Sentiment analysis analyzes your KOL’s sentiments towards products, companies, brands and focus areas to understand whether these opinions are positive, negative, or neutral. Sentiment analysis helps pharma companies to engage with KOLs.
Launching a biopharma product is a complex process. The effectiveness of multiple factors, such as a strong pre-launch medical strategy, the role of key healthcare professionals, strategic resource allocation, and launch targeting strategy, often defines a successful launch.
Badal Shah, visionary Founder and President of Neolytica, has been named the 2023-2024 Global Indian of the Year in Healthcare. This prestigious award recognizes Badal’s expertise that has contributed to cutting-edge technologies like Generative AI, NLP, and data analytics.
MORRISTOWN, N.J – QPharma, a compliance and commercial services leader in the life sciences industry, is thrilled to announce Mr. Badal Shah, B.Pharm, M.B.S, as President of Neolytica, its healthcare analytics division.
In the ever-evolving landscape of the BioPharma industry, the need for innovative approaches has become more pressing than ever. As traditional marketing channels lose their effect, the industry embraces unconventional methods to identify Key Opinion Leaders (KOLs) and boost commercial sales. This paradigm shift is not just a response to changing times; it’s a proactive strategy to stay ahead in a dynamic environment.
In the dynamic landscape of the biopharma industry, where innovation and clinical expertise must converge, it’s not just the well-known figures that make a significant impact. While the superstars often grab the spotlight, there’s an equally vital realm populated by niche experts. These individuals possess specialized knowledge that holds the key to advancing patient care and medical breakthroughs.
In the ever-evolving landscape of the pharmaceutical industry, market access has become a critical factor in the success of new therapies and products. Gaining reimbursement and securing formulary positioning are essential for ensuring patient access to innovative treatments. In this comprehensive blog post, we will delve into the significant role played by Key Opinion Leaders (KOLs) in enhancing the market access influence network.
In the fiercely competitive pharmaceutical industry, an effective influence strategy is paramount for achieving market access and commercial success. Regional key decision makers, such as formulary committees, reimbursement authorities, and healthcare administrators, hold significant sway over access to therapies.
Relationships are the key to success, and building a strong network of advisors can be the difference between a stagnant business and one that thrives. In this case study, we’ll explore the Orbital Theory of Influence, and how you can use it to maximize the effectiveness of your advisory board. We’ll also discuss the steps you need to take to ensure that your board is functioning optimally and providing the greatest benefit for your business.
In today’s dynamic healthcare landscape, relying solely on syndicated Key Opinion Leader (KOL) databases is no longer sufficient for pharmaceutical companies aiming to establish themselves as industry leaders. As disease management evolves and personalized treatment regimens become the norm, the need for real-time data and insights about KOLs has become paramount.
